streptococcus pyogenes

Cefuroxime Sodium is the sodium salt form of cefuroxime and a semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic with bactericidal activity. Cefuroxime sodium (Cefuroxime sodium salt) inhibits bacterial cell wall synthesis by inactivating penicillin binding proteins (PBPs) thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of the cell wall. Lack of cross-linking results in a reduction of cell wall stability and leads to cell lysis.

Zabofloxacin is a potent and seletive bacterial type II and IV topoisomerases inhibitor, and has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia.

Zabofloxacin hydrochloride is a potent and seletive bacterial type II and IV topoisomerases inhibitor, has excellent activity against gram-positive pathogens including Steptococcus aureus, Streptococcus pyogenes and S.pneumonia.

KKL-40 is a small-molecule inhibitor that targets the trans-translation process, effectively suppressing methicillin-sensitive and resistant Staphylococcus aureus (S. aureus) and other Gram-positive pathogens, including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. It works in synergy with the human antimicrobial peptide LL-37 to inhibit S. aureus, but does not show synergistic effects with other antibiotics such as daptomycin, kanamycin, or erythromycin. KKL-40 inhibits trans-translation, an extreme form of recoding, while being non-toxic to HeLa cells.

SrtA-IN-1 (Compound T10) is an inhibitor of Streptococcus pyogenes sortase A (SpSrtA) with an IC50 value of 0.7 μM. It is applicable for research in the field of anti-infective agents.

BRD0539 is a cell-permeable spCas9 inhibitor that blocks the binding of spCas9 to DNA and inhibits Streptococcus pyogenes Cas9 (SpCas9).

Bederocin (REP8839)is a novel inhibitor of methionyl tRNA synthase (METS) with potent antibacterial activity against clinical isolates of Staphylococcus aureus, Streptococcus pyogenes, and other clinically important Gram-positive bacteria.

Cefuroxime (Cephuroxime) is an orally active second-generation cephalosporin antibiotic with antimicrobial activity that inhibits both Gram-positive and Gram-negative bacteria, and is used in the study of soft tissue infections.

Acetyl-Adhesin (1025-1044) amide, a 20-peptide fragment derived from the cell surface adhesin of Streptococcus pyogenes, functions as an antimicrobial peptide. It specifically prevents Streptococcus pyogenes recolonization by inhibiting the adhesin's binding to salivary receptors [1].

Cefmatilen (S-1090) is an orally administered cephalosporin antibiotic that exhibits high activity against a variety of Gram-positive and Gram-negative bacteria, including Streptococcus pyogenes and Neisseria gonorrhoeae.

Paulomenol A exhibits activity against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.

Paulomenol B exhibits activity against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.

Memnopeptide A is a terpenoid peptide that activates SERCA2. Memnopeptide A exhibits mild resistance against Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus pyogenes.

Citreamicin alpha (LL-E 19085-alpha) is an antibiotic that has been evaluated for its in vitro antibacterial activity against 429 clinical isolates of Gram-positive cocci using the agar dilution method. This study included 313 strains of staphylococci and 116 strains of streptococci. Its in vitro efficacy was compared with ampicillin, amoxicillin, cephalothin, erythromycin, and vancomycin. For staphylococci, Citreamicin alpha demonstrated MIC values ranging from 0.12 to 4.0 μg/ml, and for Streptococcus pyogenes, the MIC values ranged from 0.03 to 0.12 μg/ml. Conversely, enterococci presented relative resistance, requiring 2.0 μg/ml to inhibit 64% of 62 tested strains. The antibiotic's in vitro efficacy significantly surpassed that of ampicillin, amoxicillin, cephalothin, and erythromycin, while it was comparable to or slightly less effective than vancomycin.

Chalcomycin is a macrolide antibiotic effective against Gram-positive Staphylococcus aureus and Streptococcus pyogenes. It protects mice from infections caused by various Staphylococcus and Streptococcus strains and exhibits no significant toxicity (LD50>2500 mg/kg).